Diagnostic accuracy and clinical value of [68Ga]Ga-FAPI-46 PET/CT for staging patients with ovarian cancer: study protocol for a prospective clinical trial

DOI: https://doi.org/10.1186/s12885-024-12461-w
IF: 4.638
2024-06-08
BMC Cancer
Abstract:[ 18 F]Fluorodeoxyglucose ([ 18 F]FDG) positron emission tomography (PET) is recommended during diagnostic work-up for ovarian cancer; however, [ 18 F]FDG PET has several inherent limitations. The novel oncologic PET-tracer fibroblast activation protein inhibitor (FAPI) has demonstrated promising results in multiple cancer types, including ovarian cancer, and could overcome the limitations of [ 18 F]FDG PET; however, high-quality clinical studies are lacking. The primary objective of the present study is to compare the diagnostic accuracy of [ 68 Ga]Ga-FAPI-46 PET/CT and [ 18 F]FDG PET/CT in ovarian cancer patients and to investigate how this potential difference impacts staging and patient management.
oncology
What problem does this paper attempt to address?